GLA and Fabry disease: Previous studies of Fabry disease treatments (agalsidase alfa, agalsidase beta and/or migalastat) have reported incidences of composite morbidity outcomes of 17%–37% of patients over 1.5–10 years.18, 29, 30, 31, 32, 33, 34, 35, 36, 37